162 related articles for article (PubMed ID: 17335564)
1. Differential expression of CD10 in prostate cancer and its clinical implication.
Dall'Era MA; True LD; Siegel AF; Porter MP; Sherertz TM; Liu AY
BMC Urol; 2007 Mar; 7():3. PubMed ID: 17335564
[TBL] [Abstract][Full Text] [Related]
2. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer.
Freedland SJ; Seligson DB; Liu AY; Pantuck AJ; Paik SH; Horvath S; Wieder JA; Zisman A; Nguyen D; Tso CL; Palotie AV; Belldegrun AS
Prostate; 2003 Apr; 55(1):71-80. PubMed ID: 12640663
[TBL] [Abstract][Full Text] [Related]
3. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
[TBL] [Abstract][Full Text] [Related]
4. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens.
De Marzo AM; Knudsen B; Chan-Tack K; Epstein JI
Urology; 1999 Apr; 53(4):707-13. PubMed ID: 10197845
[TBL] [Abstract][Full Text] [Related]
5. CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.
Voutsadakis IA; Vlachostergios PJ; Daliani DD; Karasavvidou F; Kakkas G; Moutzouris G; Melekos MD; Papandreou CN
Urol Int; 2012; 88(2):158-64. PubMed ID: 22286396
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence.
Velasco A; Hewitt SM; Albert PS; Hossein M; Rosenberg H; Martinez C; Sagalowsky AI; McConnell JD; Marston W; Leach FS
Cancer; 2002 Feb; 94(3):690-9. PubMed ID: 11857301
[TBL] [Abstract][Full Text] [Related]
7. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
8. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.
Hoedemaeker RF; Rietbergen JB; Kranse R; Schröder FH; van der Kwast TH
J Urol; 2000 Aug; 164(2):411-5. PubMed ID: 10893598
[TBL] [Abstract][Full Text] [Related]
9. HSP27 and HSP70 interact with CD10 in C4-2 prostate cancer cells.
Dall'Era MA; Oudes A; Martin DB; Liu AY
Prostate; 2007 May; 67(7):714-21. PubMed ID: 17342744
[TBL] [Abstract][Full Text] [Related]
10. p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer.
Revelos K; Petraki C; Gregorakis A; Scorilas A; Papanastasiou P; Tenta R; Koutsilieris M
In Vivo; 2005; 19(5):911-20. PubMed ID: 16097446
[TBL] [Abstract][Full Text] [Related]
11. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Gomella LG; Raj GV; Moreno JG
J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
[TBL] [Abstract][Full Text] [Related]
12. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
13. CD10 expression pattern in prostatic adenocarcinoma: Elucidation of differences between Gleason's grades.
Kaur M; Verma S; Gupta R; Pant L; Singh S
Malays J Pathol; 2018 Apr; 40(1):57-60. PubMed ID: 29704385
[TBL] [Abstract][Full Text] [Related]
14. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
15. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
18. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
[TBL] [Abstract][Full Text] [Related]
19. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.
Gao CL; Dean RC; Pinto A; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW
J Urol; 1999 Apr; 161(4):1070-6. PubMed ID: 10081840
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]